Degradation Kinetics by MAO of PEA Derivatives. A Model for the Molecular Basis of their Analgesic and Behavioral Effects?
The classical endogenous noncatecholic phenylethylamines, phenylethylamine (PEA), phenylethanolamine, p-tyramine and p-octopamine appear to be involved in peripheral and central nervous system synaptic transmission mechanisms (1,2). The physiological and pharmacological actions of PEA appear of particular importance as alterations in the metabolism of this amine has been postulated to contribute to the pathophysiology of a number of neuropsychiatric disorders (3–7), migraine (8,9) and diabetes (10). In order to better understand the molecular basis of PEA actions we have examined the relationship between the chemical structure, the analgesic activity and kinetic parameters of degradation by monoamine oxidase (MAO) of a series of monosubstituted derivatives of PEA.
KeywordsMonoamine Oxidase Degradation Kinetic Monosubstituted Derivative Platelet Monoamine Oxidase Shriner Hospital
Unable to display preview. Download preview PDF.
- 1.Mosnaim A. D. and Wolf M. E. (eds.) (1978) Non-catecholic Phenylethylamines, Part I:Phenylethylamine; Biological Mechanisms and Clinical Aspects. Marcel Dekker, New York.Google Scholar
- 2.Mosnaim A. D. and Wolf M. E. (eds.) (1980) Non-catecholic Phenylethylamines, Part 2: Phenylethanolamine, Tyramines and Octopamine. Marcel Dekker, New York.Google Scholar
- 8.Diamond S., Dalessio D., Graham J., and Medina J. L. (eds.) (1975) Vasoactive Substances Relevant to Migraine. Charles C. Thomas, New York.Google Scholar
- 9.Mosnaim A. D., Wine R., Karoum F., Diamond S. and Wolf M. E. (1982) Methionine enkephalin, phenylethylamine, phenylacetic acid, platelet monoamine oxidase, and prolactin in plasma of migraine patients. Clinical Pharmac. and Therap. 31, 251–252.Google Scholar
- 11.Zeller E. A., Mosnaim A. D., Borison R. L., and Huprikar S. V. (1976) Phenylethylamine: Studies on the mechanism of its physiological action, in Advances in Biochemical Psychopharmacology, Vol. 15: First and Second Messengers—New Vistas, pp. 75–86. Raven Press, New York.Google Scholar
- 13.Ehrenpreis S., Balagot R. C., Comaty J. E., and Myles S. B. (1979) Advances in Pain Research and Therapy, Vol. 3, pp. 479–488. Raven Press, New York.Google Scholar
- 16.Mosnaim A. D., Vazquez A., and Nair V. (1982) First World Congress on Toxicology and Environmental Health, Washington, D. C. (Abst.).Google Scholar
- 20.Dourish C. T. (1982) A pharmacological analysis of the hyperactivity syndrome induced by 3-phenylethylamine in the mouse. Br. J. Pharmac. 77, 129–139.Google Scholar